Mesenchymal Stromal Cells in Osteoarthritis: Evidence for Structural Benefit and Cartilage Repair

Area of Science:

• Regenerative Medicine
• Orthopedics
• Rheumatology

Background:

• Osteoarthritis (OA) poses a significant clinical challenge with limited treatments for structural degradation.
• Mesenchymal stromal cells (MSCs) offer potential therapeutic strategies for cartilage regeneration in OA.
• Current OA therapies lack agents that effectively reduce structural damage.

Purpose of the Study:

• To review the latest knowledge on Mesenchymal stromal cells (MSCs) for osteoarthritis (OA) treatment.
• To highlight the chondrogenic and immunomodulatory potential of MSCs.
• To assess the structural benefits and cartilage regeneration capabilities of MSCs in OA.

Main Methods:

• Review of preclinical and clinical studies on MSC therapy for OA.
• Comparison of different Mesenchymal stromal cells (MSCs) sources, focusing on adipose tissue-derived MSCs.
• Summarization of current evidence for cartilage assessment using MRI and arthroscopy post-MSC therapy.

Main Results:

• Adipose tissue-derived Mesenchymal stromal cells (MSCs) show promise in OA treatment.
• MSCs demonstrate chondrogenic and immunomodulatory potential relevant to OA.
• Magnetic resonance imaging (MRI) and arthroscopy are key for evaluating cartilage changes after MSC therapy.

Conclusions:

• Mesenchymal stromal cells (MSCs), especially from adipose tissue, represent a promising therapeutic avenue for osteoarthritis.
• Further research into enhancing MSC activity could improve their therapeutic efficacy in OA.
• MSC therapy shows potential for structural benefits and cartilage regeneration in OA patients.